VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 75 filers reported holding VIRIDIAN THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $25,743,695 | -35.5% | 1,678,207 | 0.0% | 2.82% | +2.3% |
Q2 2023 | $39,924,545 | -6.5% | 1,678,207 | 0.0% | 2.76% | -7.0% |
Q1 2023 | $42,693,586 | +86994.2% | 1,678,207 | 0.0% | 2.96% | -47.5% |
Q4 2022 | $49,020 | -99.9% | 1,678,207 | +1.1% | 5.64% | +50.1% |
Q3 2022 | $34,047,000 | +126.4% | 1,660,019 | +27.7% | 3.76% | +148.9% |
Q2 2022 | $15,041,000 | -37.4% | 1,300,000 | 0.0% | 1.51% | -8.8% |
Q1 2022 | $24,037,000 | -6.5% | 1,300,000 | 0.0% | 1.66% | +6.8% |
Q4 2021 | $25,701,000 | +20.2% | 1,300,000 | 0.0% | 1.55% | +61.5% |
Q3 2021 | $21,385,000 | – | 1,300,000 | – | 0.96% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VR Adviser, LLC | 2,699,865 | $68,684,566 | 13.41% |
COMMODORE CAPITAL LP | 2,189,659 | $55,704,925 | 8.48% |
Fairmount Funds Management LLC | 1,369,623 | $34,843,209 | 5.99% |
Paradigm Biocapital Advisors LP | 2,085,698 | $53,060,157 | 5.03% |
Octagon Capital Advisors LP | 1,185,000 | $30,146,400 | 4.34% |
Logos Global Management LP | 950,000 | $24,168,000 | 3.46% |
TCG Crossover Management, LLC | 663,610 | $16,882,238 | 3.29% |
ACUTA CAPITAL PARTNERS, LLC | 168,000 | $4,273,920 | 3.15% |
Vivo Capital, LLC | 1,678,207 | $42,693,586 | 2.96% |
TANG CAPITAL MANAGEMENT LLC | 692,925 | $17,628,012 | 2.63% |